

# Lung Committee

## Leadership

Chair: ..... Jhanelle E. Gray, MD  
 Vice-Chair: ..... Roy S. Herbst, MD, PhD  
 Executive Officer: ..... Anne Chiang, MD, PhD  
 Statisticians: ..... Mary Redman, PhD  
 ..... Yingqi Zhao, PhD  
 ..... Katherine Minichiello, MS  
 ..... Jieling Miao, MS  
 ..... James Moon, MS  
 ..... Lu Qian, MS

## Scientific Leadership

Translational Medicine:  
 Biology/Pathology: ..... Philip C. Mack, PhD  
 ..... Fred R. Hirsch, MD, PhD  
 ..... Ignacio I. Wistuba MD  
 Imaging: ..... Chadwick L. Wright MD, PhD  
 ..... Myrna C. Godoy, MD, PhD  
 Radiation Oncology: ..... Roy H. Decker, MD, PhD  
 Surgery: ..... Wayne L. Hofstetter, MD  
 Subcommittee Chairs:  
 Early Stage Disease: ..... Wayne L. Hofstetter, MD  
 ..... Raymond Osarogiagbon, MD  
 Locally Advanced Disease: ..... Roy H. Decker, MD, PhD  
 ..... Shirish Gadageel, MD (Early Therapeutics)  
 Metastatic Disease: ..... Ross Camidge, MD  
 ..... Karen Reckamp, MD  
 Community Engagement: ..... Paul J. Hesketh, MD  
 ..... Suzanne Cole, MD

## Designates

Cancer Control Liaison: ..... Gary E. Goodman, MD  
 DEI Champion: ..... Lucy Gansauer, MSN, RN, OCN, CCRP  
 Veterans Affairs: ..... Chao H. Huang, MD  
 ..... Cheryl M. Czerlanis, MD  
 Data Coordinators: ..... Leah Everhart  
 ..... Louise Highleyman  
 ..... Larry Kaye  
 ..... Amy Johnson  
 Clinical Research Project Manager: ..... TBD  
 Oncology Research Professionals:  
 CRAs: ..... Courtney L. Williamson  
 ..... Ginny M. Keeling, MS  
 Nurses: ..... Kimberly M. Belzer, MS, PAC  
 ..... Rosalie Zablocki, RN  
 Patient Advocate: ..... Judy Johnson, MBA

Pharmaceutical Science: ..... Joyce Lee, PharmD  
 ..... Kimberly McConnell, PharmD  
 Protocol Project Managers: ..... Mariah Norman  
 ..... Laura Gildner, MS (Lung-MAP)  
 ..... Jennifer Beeler (Lung-MAP)  
 Clinical Trials Program Manager: ..... Crystal Miwa

## Time/Location

Friday, October 21, 2022 4:15 pm - 7:15 pm  
 Room: Regency C (Ballroom Level, West Tower)

## Agenda

- 4:15 - 4:25 pm** General Update: Jhanelle E. Gray, MD
- 4:25 - 4:35 pm** Patient Advocate Update: Judy Johnson, MBA
- 4:35 - 4:45 pm** Thoracic Surgery Session: Wayne Hofstetter, MD
- 4:45 - 4:55 pm** Thoracic Radiation Session: Megan Daly, MD
- 4:55 - 5:05 pm** Translational Medicine Session: Phillip C. Mack, PhD
- 5:05 - 5:15 pm** Community Engagement Core: Paul J. Hesketh, MD
- 5:15 - 5:25 pm** DEI Session: Lucy Gansauer, MSN, RN
- 5:25 - 5:45 pm** Scientific Presentation #1  
 Patricia A. Robinson, MD  
 Assistant Dean - Diversity, Equity and Inclusion, SSOM, Associate  
 Professor of Medicine, Hematology Oncology, Loyola Medicine
- 5:45 - 6:45 pm** Thoracic Medical Oncology Session: Jhanelle Gray, MD
- 6:45 - 7:15 pm** Scientific Presentation #2  
 A Randomized Study of Pembrolizumab plus Ramucirumab Versus  
 Standard of Care for Patients Previously Treated with Immunotherapy for  
 Stage IV or Recurrent Non-Small Cell Lung Cancer  
 Karen L. Reckamp, MD  
 Directory of the Division of Medical Oncology, Medical Director of the  
 Women’s Guild Lung Institute, Associate Director for Clinical Research,  
 Department of Medicine, Cedars-Sinai Center

## Active Studies

**LUNGMAP**, “A Master Protocol to Evaluate Biomarker-Driven Therapies and  
 Immunotherapies in Previously-Treated Non-Small Cell Lung

# Lung Committee

Cancer (Lung-MAP Screening Study).” Drs. Herbst, Patel, Gandara, et al. Activation: 1/28/19.

**S1800D**, “A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study).” Drs. Wrangle and Husain. Activation: 2/15/22.

**S1900E**, “A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study).” Drs. Padda and Gerber. Activation: 4/2/21.

**S1900F**, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study).” Drs. Gray and Elamin. Activation: 7/25/22.

**S1701**, “A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma.” Drs. Tsao and Koczywas. Activation: 8/9/18.

**S1827**, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

**S1914**, “A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC.” Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

**S1929**, “Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC).” Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22.

**S1933**, “A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status.” Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

**S1934**, “NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small

Cell Lung Cancer.” Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22.

**CTSU/EA5163/S1709**, “INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis.” Dr. Chiang. Activation: 2/28/19.

**CTSU/A081801**, “Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO).” Dr. Gray. Activation: 6/3/20.

**CTSU/A151216**, “Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).” Dr. Gandara. Activation: 8/18/14.

**CTSU/E4512**, “A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.” Dr. Li. Activation: 8/18/14.

**CTSU/EA5181**, “Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC.” Dr. Harkenrider. Activation: 4/9/20.

**CTSU/EA5182**, “Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC).” Dr. Goldberg. Activated:10/22/20.

**CTSU/EA5191**, “A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC.” Dr. Massarelli. Activated: 5/22/20.

**CTSU/NRG-LU002**, “Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial.” Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21.

**CTSU/NRG-LU005**, “Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.” Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22.

**CTSU/NRG-LU007**, “Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial.” Dr. Park. Activated: 8/17/20.

# Lung Committee

## Closed Studies

**CTSU/NRG-CC003**, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

**S1900A**, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

**S1900B**, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

**S1900C**, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

**S1800A**, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

## NCI-Approved Concepts

**S1900G**, "A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge.

**S2302**, "PROJECT PRAGMATICA: A Prospective Randomized Study of Ramucirumab (NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-small Cell Lung Cancer in Standard Practice." Drs. Reckamp and Dragnev.

## Concepts in Development

**S1900I**, "A Randomized Phase II study of Mobocertinib (TAK-788) with or without Ramucirumab in Participants with Previously Treated EGFR Exon 20 Insertion Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Doroshow and Patel.

**S1800E**, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp, Dragnev, and Waqar.

**S1800F**, "A Phase II Study Of MK7684A (coformulation of Vibostolimab plus Pembrolizumab) in combination with Lenvatinib versus Standard of Care in Patients with Anti-PD-1 or Anti-PD-L1 Relapsed and Refractory Stage IV Non-Small Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)." Drs. Massarelli and Li.

## Lung Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900B	S1900E	S1914	S1929	S1933	A081105	A081801
Ascension Prov Hosp - Southfield	13	-	-	-	-	-	-	1	-	-	-
Ascension Via Christi Hosp Wichita	1	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	-	-	-	1	-	-	-	-	-	-	1
Banner U Med Ctr - Tucson	-	-	-	-	-	-	-	-	-	-	-
Baptist Mem HC/Mid South MU NCORP	34	-	-	-	-	1	4	2	-	-	1
Baylor College of Med/Dan L Duncan CCC	-	-	-	1	-	-	-	-	-	-	-
Boston Med Ctr	-	-	-	4	-	-	-	-	-	-	-
CWRU Case CCC LAPS	10	-	-	-	-	2	-	-	-	6	4
Ca Res Consort of W Mich NCORP	3	-	-	-	-	-	2	-	-	-	-
Ca Res for the Ozarks NCORP	29	-	1	-	-	-	-	2	3	1	-
Ca Res of Wisconsin & N Mich Consort	23	-	1	-	-	3	-	-	-	-	-
Carle CC NCORP	2	-	-	-	-	-	2	-	-	-	-
Cedars-Sinai Med Ctr	7	-	-	-	-	1	-	-	-	-	-
City of Hope CCC	5	1	-	1	-	-	-	-	-	1	-
Columbia U MU NCORP	8	-	-	-	-	-	-	-	-	-	-
Columbus NCORP	26	-	-	3	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	43	-	-	-	-	-	1	2	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	-
Dayton NCORP	2	-	-	-	-	-	-	1	-	-	1
Essentia Hlth NCORP	15	-	2	-	-	-	1	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	4	-	-	-	-	-	-	-	-	1	-
Georgia Cares MU NCORP	6	-	-	1	-	-	2	3	1	-	-
Georgia NCORP	50	-	-	2	-	1	2	-	-	-	-
Gulf South MU NCORP	8	-	-	1	-	-	1	1	-	-	-
Hawaii MU NCORP	21	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	108	-	-	2	1	4	18	16	2	-	-
Henry Ford Hospital	7	-	-	-	-	-	-	1	-	2	2
Houston Methodist Hosp	-	-	-	-	-	-	-	-	-	2	-
Kaiser Permanente NCORP	60	-	1	-	-	6	1	-	-	19	2
Lahey Hospital & Med Ctr	29	-	-	-	-	-	1	1	2	-	-
Loma Linda U Med Ctr	5	-	-	-	-	-	-	-	-	3	-
Loyola U Med Ctr	22	-	-	-	-	-	-	1	-	-	-
Massachusetts Vet Epi Res & Info Ctr	39	-	1	1	-	-	-	-	-	1	6
Medical U South Carolina MU NCORP	10	-	-	-	-	1	-	-	-	-	-
Michigan Ca Res Consort NCORP	99	-	4	-	-	4	1	1	-	-	-
Moffitt CC	9	2	-	1	-	1	-	-	-	3	6
Montana Cancer Consort NCORP	24	-	-	-	-	-	-	3	1	-	-
Mount Sinai Hospital	-	-	-	-	-	-	7	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	15	-	-	-	-	1	-	-	-	-	-

## Lung Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900B	S1900E	S1914	S1929	S1933	A081105	A081801
Nevada Ca Res Foundation NCORP	12	-	-	-	-	-	-	1	-	-	-
New Mexico MU NCORP	66	-	-	1	-	-	5	5	1	-	-
Northwell Hlth NCORP	-	-	-	-	-	-	-	-	-	-	1
Northwestern U LAPS	23	1	-	1	-	-	-	3	-	-	-
Oregon Hlth & Science U	1	-	-	-	-	-	1	-	-	1	5
Pacific Ca Res Consort NCORP	14	-	-	-	-	-	-	3	-	-	-
SCL Hlth Saint Joseph Hospital	1	-	-	-	-	-	1	-	-	-	1
Salem Hospital	3	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	45	-	-	4	-	-	3	5	-	-	-
Sutter Ca Res Consort	22	-	-	-	-	1	-	-	-	1	-
The Don and Sybil Harrington CC	7	-	1	-	-	-	-	-	-	-	-
The James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	26	3	5	1	-	-	6	2	-	4	-
UC Irvine Hlth/Chao Family CCC	18	-	-	1	-	-	1	-	-	2	-
UC San Diego Moores CC	11	-	-	-	-	1	-	-	-	1	-
UPMC Hillman CC LAPS	27	-	-	2	-	5	-	1	2	-	-
USC Norris CCC LAPS	-	-	-	1	-	-	3	-	-	1	-
U Arkansas for Medical Sciences	11	-	-	-	-	-	5	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-	-	1	-
U Colorado CC LAPS	10	-	-	1	-	-	3	2	-	9	3
U Kansas CC - MCA Rural MU NCORP	79	-	1	-	-	1	-	-	-	1	-
U Kentucky/Markey CC	42	-	-	1	-	-	-	-	-	1	-
U Michigan CCC LAPS	1	-	-	-	-	-	-	-	-	1	-
U Mississippi Med Ctr	1	-	-	-	-	-	-	-	-	2	-
U Oklahoma Hlth Sciences Ctr LAPS	28	-	-	1	-	-	-	1	8	-	-
U Rochester LAPS	53	-	1	-	-	5	2	-	-	-	-
U Texas Hlth Science Ctr at San Antonio	-	-	-	-	-	-	-	1	-	-	-
U Texas MD Anderson CC LAPS	3	6	-	-	-	-	-	4	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	1	-	-	2	1	-	-	-
Upstate Carolina Consort NCORP	32	-	-	-	-	-	1	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	-
Western States Ca Res NCORP	2	-	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	37	-	-	1	-	-	5	-	-	-	-
Yale U - Yale CC LAPS	17	-	-	2	-	-	-	-	-	3	3
ALLIANCE	620	3	3	11	1	13	5	7	2	-	-
CCTG	-	-	-	11	-	-	-	-	-	-	-
ECOG-ACRIN	298	2	3	2	2	11	9	7	-	-	-
NRG	316	-	1	42	2	4	13	5	1	-	-
<b>Total</b>	<b>2,564</b>	<b>18</b>	<b>25</b>	<b>102</b>	<b>6</b>	<b>66</b>	<b>108</b>	<b>83</b>	<b>23</b>	<b>67</b>	<b>36</b>

# Lung Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	A151216	E4512	E45163	E45181	E45182	E45191	NRGCC003	NRGLU002	NRG0005	R1308
Ascension Prov Hosp - Southfield	14	1	2	3	-	1	-	-	-	-
Ascension Via Christi Hosp Wichita	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	1	-	-	-	-	-	-	-	2	-
Banner U Med Ctr - Tucson	7	2	-	4	-	-	-	-	1	-
Baptist Mem HC/Mid South MU NCORP	21	-	1	-	-	-	-	1	4	-
Baylor College of Med/Dan L Duncan CCC	-	-	-	-	-	-	-	-	-	-
Boston Med Ctr	3	-	-	1	-	-	-	-	-	-
CWRU Case CCC LAPS	48	-	8	14	-	-	-	-	-	-
Ca Res Consort of W Mich NCORP	1	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	1	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	-	-	-	-	-	-	-	-	-	-
Carle CC NCORP	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	-	-	-	-	-	-	-	-	-
City of Hope CCC	4	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	-	-	-	-	-	-	-	-
Columbus NCORP	-	-	-	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	2	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	3	-	-	-	-	-	-	-	-	-
Dayton NCORP	8	-	-	-	-	-	-	-	-	-
Essentia Hlth NCORP	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	15	-	-	-	-	-	-	-	-	-
Georgia Cares MU NCORP	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	9	-	1	-	-	-	-	-	-	-
Gulf South MU NCORP	-	-	3	-	-	-	-	-	-	-
Hawaii MU NCORP	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	-	-	-	-	1	-	-	-
Henry Ford Hospital	29	-	-	-	-	-	-	-	-	-
Houston Methodist Hosp	8	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	199	4	5	-	1	-	-	-	-	-
Lahey Hospital & Med Ctr	30	-	2	-	-	-	-	-	-	-
Loma Linda U Med Ctr	9	-	-	-	-	-	-	-	-	1
Loyola U Med Ctr	21	-	-	2	-	-	-	-	-	-
Massachusetts Vet Epi Res & Info Ctr	25	-	3	-	-	2	-	-	-	-
Medical U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	-	-	-	-	-	-	-	-	-	-
Moffitt CC	83	1	-	-	-	-	-	-	-	-
Montana Cancer Consort NCORP	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	-	-	-	-	1	-
NCORP Carolinas (Prisma Hlth NCORP)	1	-	-	-	-	-	-	-	-	-

## Lung Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	A151216	EA512	EA5163	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	R1308
Nevada Ca Res Foundation NCORP	-	-	-	-	-	-	-	-	-	-
New Mexico MU NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Hlth NCORP	1	-	-	-	-	-	-	-	-	-
Northwestern U LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Hlth & Science U	20	-	-	-	-	-	-	-	-	-
Pacific Ca Res Consort NCORP	4	-	-	-	-	-	-	-	-	-
SCL Hlth Saint Joseph Hospital	2	-	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consort	10	-	-	2	-	-	-	-	-	-
The Don and Sybil Harrington CC	-	-	-	-	-	-	-	-	-	-
The James Graham Brown CC at U Louisville	5	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	41	1	6	-	1	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	13	-	-	-	-	-	-	-	-	-
UC San Diego Moores CC	5	-	-	-	-	-	-	-	-	-
UPMC Hillman CC LAPS	-	-	-	-	-	-	-	-	1	-
USC Norris CCC LAPS	12	-	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	2	-	1	-	-	-	-	-	1	-
U Cincinnati CC-UC Med Ctr	22	1	-	-	1	-	-	-	-	-
U Colorado CC LAPS	58	2	-	-	-	1	-	-	1	-
U Kansas CC - MCA Rural MU NCORP	28	-	5	-	-	1	-	-	2	-
U Kentucky/Markey CC	5	-	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	62	-	-	-	-	-	-	-	-	-
U Mississippi Med Ctr	26	-	-	-	-	-	-	-	-	-
U Oklahoma Hlth Sciences Ctr LAPS	-	-	-	-	-	-	-	-	-	-
U Rochester LAPS	-	-	2	13	-	-	4	-	1	-
U Texas Hlth Science Ctr at San Antonio	-	-	2	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	2	1	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	1	-	-	-	-	-	-	-
Upstate Carolina Consort NCORP	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	1	-	-
Western States Ca Res NCORP	1	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	2	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	52	4	10	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>916</b>	<b>17</b>	<b>52</b>	<b>40</b>	<b>3</b>	<b>5</b>	<b>5</b>	<b>2</b>	<b>14</b>	<b>1</b>